Immix Biopharma, Inc. IMMX Weighted Average Exercise Price of Exercisable Options
Weighted Average Exercise Price of Exercisable Options at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s weighted average exercise price of exercisable options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s weighted average exercise price of exercisable options?
- Immix Biopharma, Inc. (IMMX) reported weighted average exercise price of exercisable options of $2.09 in Q1 2026.
- How has Immix Biopharma, Inc.'s weighted average exercise price of exercisable options changed year-over-year?
- Immix Biopharma, Inc.'s weighted average exercise price of exercisable options increased by 5.6% year-over-year, from $1.98 to $2.09.
- What is the long-term trend for Immix Biopharma, Inc.'s weighted average exercise price of exercisable options?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s weighted average exercise price of exercisable options has grown at a 11.6% compound annual growth rate (CAGR), from $1.33 to $2.06.
- What does weighted average exercise price of exercisable options mean?
- This is the average price at which holders of vested stock options can purchase shares of the company's common stock. It is a key indicator of the potential future dilution and the alignment of employee incentives with shareholder interests.